ABBV trades 1.3% below Wall Street's consensus target of $258.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ABBV achieves its forward estimates and maintains a stable P/E multiple of 17.9x. This scenario reflects the blended consensus of 41 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, AbbVie Inc. (ABBV) has a Wall Street consensus price target of $258.00, based on estimates from 41 covering analysts. With the stock currently trading at $254.76, this represents a potential upside of +1.3%. The company has a market capitalization of $450.11B.
Analyst price targets range from a low of $223.00 to a high of $298.00, representing a 29% spread in expectations. The median target of $260.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 28 analysts rating the stock as a Buy or Strong Buy,12 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, ABBV trades at a trailing P/E of 107.5x and forward P/E of 17.9x. Analysts expect EPS to grow +593.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $392.79, with bear and bull scenarios of $247.46 and $517.54 respectively. Model confidence stands at 55/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
JNJJohnson & Johnson | $624.3B | $259.33 | $253.42 | -2.3% | Buy | 22.4x | 40 |
MRKMerck & Co., Inc. | $313.1B | $126.78 | $133.77 | +5.5% | Buy | 24.7x | 37 |
PFEPfizer Inc. | $134.9B | $23.72 | $26.75 | +12.8% | Hold | 8.0x | 39 |
BMYBristol-Myers Squibb Company | $115.8B | $56.70 | $62.60 | +10.4% | Hold | 9.0x | 41 |
LLYEli Lilly and Company | $1.1T | $1200.06 | $1269.94 | +5.8% | Buy | 32.8x | 45 |
AMGNAmgen Inc. | $197.8B | $366.44 | $352.50 | -3.8% | Buy | 16.4x | 38 |
GILDGilead Sciences, Inc. | $160.9B | $129.61 | $161.81 | +24.8% | Buy | — | 58 |
BIIBBiogen Inc. | $30.8B | $208.46 | $218.32 | +4.7% | Buy | 14.4x | 48 |
REGNRegeneron Pharmaceuticals, Inc. | $67.5B | $649.81 | $836.00 | +28.7% | Buy | 14.0x | 48 |
SNYSanofi | $102.4B | $42.61 | $51.00 | +19.7% | Hold | 10.1x | 27 |
Quick answers to the most common questions about buying ABBV stock.
The consensus price target for ABBV is $258, close to the current price of $254.76 (1.3% implied move). Based on 41 analyst estimates, the stock appears fairly valued near current levels.
ABBV has a consensus rating of "Buy" based on 41 Wall Street analysts. The rating breakdown is predominantly bullish, with 28 Buy/Strong Buy ratings. The consensus 12-month price target of $258 implies 1.3% upside from current levels.
With a forward P/E of 17.9049x, ABBV trades at a relatively low valuation. The consensus target of $258 implies 1.3% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $298 for ABBV, while the most conservative target is $223. The consensus of $258 represents the median expectation. Our quantitative valuation model projects a bull case target of $518 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
ABBV is heavily covered by Wall Street, with 41 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 28 have Buy ratings, 12 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ABBV stock forecast based on 41 Wall Street analysts shows a consensus price target of $258, with estimates ranging from $223 (bear case) to $298 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $393, with bear/bull scenarios of $247/$518.
Our quantitative valuation model calculates ABBV's fair value at $393 (base case), with a bear case of $247 and bull case of $518. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 55/100.
ABBV trades at a forward P/E ratio of 17.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 107.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
ABBV appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $258 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ABBV analyst price targets range from $223 to $298, a 29% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $258 consensus represents the middle ground. Our model's $247-$518 range provides an independent fundamental perspective.
Wall Street verdict, signals, and target summaries.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.